AOD-9604 and blood work: what actually needs monitoring

Last updated 2026-07-24

Does AOD-9604 show up on standard blood tests?

No, not in the way people expect. Standard metabolic panels, lipid panels, and full blood chemistry tests aren't designed to detect a specific peptide fragment like AOD-9604 sitting in your bloodstream. They measure downstream markers: glucose, triglycerides, liver enzymes, kidney function. None of those panels have a validated line item for AOD-9604 itself. Detecting the actual peptide requires specialized mass spectrometry work, the kind used in anti-doping labs, not a Quest or LabCorp panel your doctor orders. Research on peptide detection in doping controls has looked at direct urine injection combined with liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa, AOD-9604 among them ^[1]. That's a research-grade forensic method, not something available through routine clinical bloodwork. So if you're asking "will my labs show I've been using AOD-9604," the honest answer is: not through anything your primary care doctor can order. The relevant question isn't whether it shows up. It's whether it does anything measurable to the markers that do show up, and that's a much shakier story.

What did the actual human trials measure, and what did they find?

This is the part that matters most, and it's the part most retailers skip. AOD-9604 went through obesity trials specifically because it's a fragment of human growth hormone (amino acids 176-191, the C-terminal region) designed to keep the fat-metabolizing activity of GH without the growth-promoting and blood-sugar-disrupting effects of the full hormone. That was the pitch: fat loss without GH's downsides. A 2004 review covering AOD-9604's development as a metabolic agent describes it in exactly that context, as an obesity-focused fragment candidate moving through investigational work ^[2]. A broader 2006 survey of obesity drugs in clinical development places AOD-9604 among the compounds being tested at that stage, alongside other anti-obesity candidates of the era ^[3]. Here's the problem. None of the available literature in this research pack, including the trial-tracking "Gateways to clinical trials" series that logged AOD-9604's progression through development in 2003 and 2005, reports a clean, clinically convincing separation from placebo on weight loss endpoints ^[4][5][6]. The compound reached Phase II development and generated real trial data, but the fat-loss signal never became the kind of unambiguous result that gets a drug to FDA approval. It isn't an FDA-approved drug for obesity or anything else. You can check that yourself in the Drugs@FDA database ^[7], where AOD-9604 doesn't appear as an approved product. That's the central fact this whole article sits on top of. If you came here hoping bloodwork could prove AOD-9604 is working, the more fundamental issue is that the human trials designed to prove it works didn't get there first.

If AOD-9604 doesn't clearly beat placebo, why do blood markers matter at all?

Because even a compound with a weak or unproven efficacy signal can still have effects on the body worth watching, and because "no clear benefit" is not the same as "no biological activity." Peptide compounds interact with metabolic pathways whether or not they deliver the fat-loss result someone's chasing. A recent review of peptide therapies in orthopaedics discusses AOD-9604 in the context of connective tissue and musculoskeletal applications being explored for GH-fragment compounds beyond the original obesity angle ^[1]. Separately, a 2026 sports medicine review evaluating safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance places AOD-9604 among compounds used off-label in performance and recovery contexts, an area with its own separate safety questions ^[8]. The honest takeaway: bloodwork in this context isn't about confirming AOD-9604 is delivering fat loss (the trial record doesn't support strong claims there). It's basic due diligence for anyone injecting a peptide from any research-chemical or compounded source, regardless of what that specific peptide is supposed to do.

What panels should someone using AOD-9604 actually ask for?

There's no AOD-9604-specific panel because there's no validated clinical claim to monitor against. What makes sense is the same baseline workup any reasonable clinician would order before and during use of an injectable peptide from an unregulated supply chain.

Ask a prescriber to order these before starting and again at a reasonable interval (many clinicians default to 8-12 weeks, though there's no published protocol specific to AOD-9604 dictating that timeline). None of this constitutes proof the peptide is working. It's just responsible baseline monitoring for anyone using an injectable compound sourced outside standard pharmacy channels.

Will AOD-9604 raise IGF-1 or affect a growth hormone test?

The design intent was no, and the limited data available supports that intent, though the evidence base is thin. AOD-9604 is a fragment of the GH molecule's C-terminal region, specifically excluding the domain responsible for binding the GH receptor and triggering the IGF-1 cascade in the liver. That's the whole premise behind the compound: fat-metabolizing activity without the receptor-mediated growth effects, including IGF-1 elevation. A 2013 study looked specifically at whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test anti-doping labs use to distinguish real growth hormone doping from background physiological hGH. The study concluded AOD-9604 does not influence that immunoassay ^[9], meaning it doesn't get flagged or confused with actual GH use on that specific test. That's a narrow, specific finding about one assay, not a broad statement about AOD-9604's overall effect on GH-axis blood markers. This matters for two separate reasons. First, if you're getting standard IGF-1 or GH-axis labs done, AOD-9604 isn't expected to move those numbers the way real GH or GH secretagogues would, because it isn't designed to activate that receptor pathway. Second, if you're an athlete subject to drug testing, the fact that it doesn't trip the standard hGH isoform test doesn't mean it's undetectable by other methods. See the next section.

Can AOD-9604 be detected in anti-doping tests?

Yes, through specialized methods, even though it doesn't interfere with the standard hGH isoform immunoassay. Anti-doping science has moved well past basic immunoassays for peptide detection, and AOD-9604 specifically shows up in that literature as a target compound. A 2014 review of analytical approaches for detecting emerging therapeutics and non-approved drugs in doping controls covers AOD-9604 among the peptide compounds requiring dedicated detection methods beyond standard hormone panels ^[10]. A companion 2014 review focused specifically on detecting peptidic drugs, drug candidates, and analogs in sports doping likewise treats AOD-9604 as part of the expanding peptide-detection landscape that anti-doping labs have had to build methods for ^[11]. On the technical side, a 2016 paper describes a method using direct urine injection with liquid chromatography and ion mobility mass spectrometry to simplify and expand screening for peptides under 2 kDa in molecular weight, a category that includes AOD-9604 ^[12]. If you're a tested athlete, the practical reality is that AOD-9604 is not a compound anti-doping labs have overlooked. It's specifically named in the analytical chemistry literature built to catch it.

Does AOD-9604 affect blood sugar or insulin sensitivity?

The available literature in this research pack doesn't include a controlled human trial reporting specific glucose or insulin sensitivity outcomes for AOD-9604 at scale. The theoretical design intent, again, was to isolate the fat-metabolizing region of GH from the region associated with GH's diabetogenic effects (real GH is well known to raise blood glucose and reduce insulin sensitivity at supraphysiologic doses). Whether AOD-9604 delivers on that separation as cleanly in practice as intended isn't something the cited literature settles with strong human outcome data. Given that gap, an HbA1c and fasting glucose as part of baseline and follow-up labs is reasonable, not because there's strong evidence of a problem, but because there's genuinely limited human safety data to lean on either way. Absence of alarming data isn't the same as evidence of safety. It just means nobody has run the large, long trial that would settle it either direction.

How does AOD-9604's trial record compare to GLP-1 drugs on actual evidence?

There's no honest comparison here. GLP-1 receptor agonists (semaglutide, tirzepatide) went through large, randomized, placebo-controlled Phase III trials with body weight as the primary endpoint, and those trials showed weight loss clearly separating from placebo, which is why they carry FDA approval for chronic weight management. You can confirm approval status directly in the Drugs@FDA database ^[7]. AOD-9604 never produced that kind of result. The compound reached Phase II development and generated trial data tracked in the pharmaceutical "Gateways to clinical trials" series ^[4][5][6], and a 2006 review of the obesity drug pipeline lists it among candidates in that era ^[3], but no study in the available record shows AOD-9604 clearing the placebo bar the way approved obesity drugs did. It is not FDA-approved for weight loss or any other indication.

If your priority is weight loss with the strongest evidence behind it, this isn't a close call. That doesn't mean AOD-9604 has zero biological activity; it means the evidence bar an approved drug has to clear is a bar AOD-9604 hasn't cleared.

Why isn't AOD-9604 FDA-approved, and does that affect what your doctor can prescribe?

AOD-9604 lacks FDA approval as a drug product, which you can verify by checking Drugs@FDA directly ^[7]. That status shapes everything about how it's legally handled, including whether a pharmacy can compound it. Compounding pharmacies operating under Section 503A of the Food, Drug and Cosmetic Act can only use bulk drug substances that appear on FDA's official 503A Bulks List, defined under 21 CFR 216.23 ^[13]. Outsourcing facilities registered under Section 503B work from a separate list under 21 CFR 216.24 ^[14]. The statutory basis for pharmacy compounding itself sits in 21 U.S.C. 353a ^[15]. Whether AOD-9604 sits on either current bulks list is something to check directly against FDA's own bulk drug substances page for 503A ^[16] and the current nominated substances list ^[17], since that status can change. This matters for blood monitoring in a practical sense: a legitimate prescriber working through a properly licensed pharmacy can build a monitoring plan around informed consent and standard labs. A source outside that structure generally can't offer that kind of clinical oversight at all.

What should someone do if they've already started AOD-9604 and want to check their bloodwork?

Get a baseline metabolic panel, lipid panel, and HbA1c now if you haven't already, even if you're several weeks into use. Late baseline data still beats no data. Ask whoever ordered your labs (or a primary care provider, if you're sourcing independently) to repeat the same panel in 8 to 12 weeks so you have a before-and-after to look at, understanding that any change could reflect diet, exercise, or unrelated factors, not necessarily the peptide. Don't expect a lab result that says "AOD-9604 is working" or "AOD-9604 is not working." That test doesn't exist in routine clinical practice. What you can reasonably track is whether your metabolic markers are moving in a direction that concerns you or reassures you, discussed with someone qualified to interpret them in context. If you're weighing whether to start at all, it's worth reading honestly about AOD-9604 as a compound before going further, and reviewing dosage information and reconstitution steps if you decide to proceed, ideally with a provider-reviewed source rather than an unverified vendor.

What are the realistic side effects to watch for, blood-related or otherwise?

The 2026 sports medicine review of peptide therapies for musculoskeletal and athletic use frames AOD-9604 among compounds with a genuinely limited human safety dataset relative to how widely they're marketed ^[8]. That's not a specific side effect list; it's a statement about how little rigorous safety surveillance exists. Common injection-related issues (site redness, swelling, mild irritation) apply to essentially any subcutaneous peptide injection, regardless of what's in the vial. Beyond that, there isn't a large, well-characterized adverse event profile specific to AOD-9604 published from placebo-controlled human trials in the sources available here. For a full breakdown of what's actually reported, read the dedicated side effects page. The short version: the safety data gap is arguably a bigger problem for a research-grade compound than the efficacy gap, because it means nobody can give you a confident answer either way.

Where AOD9604Co fits into this

AOD9604Co reviews providers so that if you decide to move forward despite the thin efficacy record, you're at least working with a provider-reviewed source and a named, legitimate fulfilling pharmacy partner rather than an anonymous vendor with no accountability. AOD9604Co doesn't compound or manufacture anything itself; it points readers toward vetted, provider-reviewed pathways. That distinction matters most for the bloodwork question specifically. A legitimate prescriber can order baseline and follow-up labs, interpret them against your actual health history, and adjust course if something looks off. An unverified peptide vendor can't do any of that, and no amount of marketing copy changes the underlying trial record.

Frequently asked questions

Does AOD-9604 show up on a standard blood test or urine drug screen?

No. Routine clinical blood and urine panels aren't built to detect AOD-9604 specifically. Detecting the actual peptide requires specialized mass spectrometry methods used in anti-doping labs, not standard clinical lab work ^[2]. It can be found through those specialized methods, just not through a typical panel your doctor would order.

Can AOD-9604 be detected in anti-doping drug tests?

Yes. While a 2013 study found AOD-9604 doesn't interfere with the WADA hGH isoform immunoassay ^[8], separate analytical chemistry literature describes dedicated methods, including mass spectrometry approaches for peptides under 2 kDa, specifically built to detect it in doping controls ^[9][10][15].

Does AOD-9604 raise IGF-1 levels?

It's not designed to. AOD-9604 is a fragment of GH's C-terminal region that excludes the receptor-binding domain responsible for triggering the liver's IGF-1 response. The limited available data supports that it doesn't trigger the standard hGH-related immunoassay response ^[8], though large human trials measuring IGF-1 specifically aren't part of the available literature.

What blood panels should I get before starting AOD-9604?

A metabolic panel, lipid panel, HbA1c, and complete blood count are reasonable baseline tests, the same panels sensible for any injectable peptide from an unregulated source. There's no AOD-9604-specific test, since no validated clinical monitoring protocol exists for this compound.

Did AOD-9604 actually work in human obesity trials?

The trial record does not show AOD-9604 clearly beating placebo on weight loss. It progressed through Phase II development tracked in pharmaceutical trial pipeline reviews ^[5][6][7] and appeared in a 2006 survey of obesity drugs in development ^[4], but no cited study shows a convincing placebo-separated result, and it holds no FDA approval ^[11].

Is AOD-9604 FDA-approved?

No. AOD-9604 does not appear as an approved drug product in the FDA's Drugs@FDA database ^[11]. It has no approved indication for weight loss or anything else in the United States.

How does AOD-9604 compare to semaglutide or tirzepatide on evidence?

Semaglutide and tirzepatide are FDA-approved for chronic weight management based on large Phase III trials showing clear placebo separation on weight loss. AOD-9604 reached only Phase II, never demonstrated a comparably clear effect in the available literature, and carries no approval ^[11].

Will AOD-9604 affect my blood sugar or HbA1c?

There's no large controlled human trial in the available literature reporting glucose or HbA1c outcomes specifically for AOD-9604. It was designed to avoid the blood-sugar effects associated with full-length GH, but that design intent hasn't been confirmed with strong human outcome data, so tracking HbA1c as a baseline measure is reasonable.

Can a compounding pharmacy legally prepare AOD-9604?

That depends on whether it appears on FDA's current bulks list for 503A pharmacies (21 CFR 216.23) ^[12] or 503B outsourcing facilities (21 CFR 216.24) ^[13]. Check FDA's bulk drug substances page directly ^[16][17] for current status, since these lists are updated over time.

What's the difference between AOD-9604 and real growth hormone on blood markers?

Real GH activates the GH receptor and raises IGF-1 through liver signaling, along with raising blood glucose at high doses. AOD-9604 is a fragment specifically excluding that receptor-binding region, and available data shows it doesn't trigger the standard hGH isoform immunoassay response ^[8], suggesting a different interaction profile, though large-scale human confirmation is limited.

Are there known safety concerns with AOD-9604 based on blood work?

A 2026 review of peptide therapies for musculoskeletal and athletic use notes that AOD-9604's human safety data is genuinely limited relative to its marketing reach ^[3]. No large-scale published trial in the available literature reports a detailed adverse blood marker profile, which is itself a limitation worth taking seriously.

Should I monitor my bloodwork while using AOD-9604?

Yes, as a general safety practice for any injectable peptide, not because there's a validated AOD-9604-specific monitoring protocol. A metabolic panel, lipid panel, and HbA1c at baseline and again in 8 to 12 weeks gives a reasonable comparison point, ideally interpreted with a qualified prescriber.

Sources

1. Current Opinion in Investigational Drugs, 2004 (PMID 15134286): AOD-9604 was developed and studied as a metabolic/obesity investigational agent based on the GH fragment rationale.
2. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews AOD-9604 and related GH-fragment peptides in orthopaedic and connective tissue applications beyond the original obesity indication.
3. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies, including AOD-9604, for musculoskeletal injury and athletic performance, noting limited human safety data.
4. Current Opinion in Investigational Drugs, 2006 (PMID 16625817): Surveys obesity drugs in clinical development in 2006, including AOD-9604 among the candidates in the pipeline at that time.
5. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14685303): Tracks AOD-9604's progression through clinical trial development pipeline reporting in 2003.
6. Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14571286): Additional 2003 clinical trial pipeline tracking entry covering AOD-9604's development stage.
7. Methods and Findings in Experimental and Clinical Pharmacology, 2005 (PMID 15834452): 2005 clinical trial pipeline tracking entry showing AOD-9604 had reached Phase II development without a reported definitive placebo-beating result.
8. Drug Testing and Analysis, 2013 (PMID 24124033): AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing.
9. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviews analytical approaches, including AOD-9604, needed to detect emerging non-approved peptide therapeutics in doping controls.
10. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews methods for detecting peptidic drugs and analogs, including AOD-9604, in sports doping analysis.
11. FDA, Drugs@FDA database: AOD-9604 does not appear as an FDA-approved drug product; can be checked directly against the approved drug database.
12. 21 CFR 216.23, the 503A Bulks List: Defines the official bulk drug substances list that 503A compounding pharmacies may legally use.
13. 21 CFR 216.24, the 503B Bulks List: Defines the separate bulk drug substances list that 503B outsourcing facilities may legally use.
14. 21 U.S.C. 353a, pharmacy compounding: Statutory basis under federal law for pharmacy compounding of drug substances.
15. Journal of Separation Science, 2016 (PMID 26578461): Describes a direct urine injection, LC and ion mobility mass spectrometry method for screening peptides under 2 kDa, applicable to AOD-9604 detection.
16. FDA, bulk drug substances used in compounding under section 503A: Current FDA guidance page for checking which bulk drug substances are permitted for 503A compounding.
17. FDA, bulk drug substances nominated for use in compounding (current list): Current list of nominated bulk drug substances under review or status for compounding use.